HDAC2: a critical factor in health and disease

被引:129
作者
Kraemer, Oliver H. [1 ]
机构
[1] Univ Jena, CMB, Inst Biochem & Biophys, D-07743 Jena, Germany
关键词
HISTONE DEACETYLASE INHIBITORS; DUCHENNE MUSCULAR-DYSTROPHY; SMOOTH-MUSCLE-CELLS; KAPPA-B ACTIVITY; PML-RAR-ALPHA; VALPROIC ACID; COLON-CANCER; ACETYLATION; EXPRESSION; CHROMATIN;
D O I
10.1016/j.tips.2009.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Histone deacetylases control cellular signaling and gene expression. Histone deacetylase 2 (HDAC2) is crucial for embryonic development, affects cytokine signaling relevant for immune responses and is often significantly overexpressed in solid tumors. Nevertheless, transformed cells lacking HDAC2 due to somatic mutations have recently been discovered. This finding has raised a question regarding the functions of this enzyme. Detailed analyses of the molecular mechanisms governing gene regulation by HDAC2 illustrate how this protein influences proliferation, apoptosis and differentiation of cells. Beyond clarifying the role of HDAC2 for cellular fate, such data position the epigenetic regulator HDAC2 as a therapeutically important prognostic marker that can be subjected to pharmacological control.
引用
收藏
页码:647 / 655
页数:9
相关论文
共 63 条
[1]   Histone Deacetylase 2 Is Phosphorylated, Ubiquitinated, and Degraded by Cigarette Smoke [J].
Adenuga, David ;
Yao, Hongwei ;
March, Thomas H. ;
Seagrave, Jeanclare ;
Rahman, Irfan .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2009, 40 (04) :464-473
[2]   Histone Deacetylases 1 and 2 Form a Developmental Switch That Controls Excitatory Synapse Maturation and Function [J].
Akhtar, Mohd W. ;
Raingo, Jesica ;
Nelson, Erika D. ;
Montgomery, Rusty L. ;
Olson, Eric N. ;
Kavalali, Ege T. ;
Monteggia, Lisa M. .
JOURNAL OF NEUROSCIENCE, 2009, 29 (25) :8288-8297
[3]   Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial [J].
Atmaca, A. ;
Al-Batran, S-E ;
Maurer, A. ;
Neumann, A. ;
Heinzel, T. ;
Hentsch, B. ;
Schwarz, S. E. ;
Hovelmann, S. ;
Goettlicher, M. ;
Knuth, A. ;
Jaeger, E. .
BRITISH JOURNAL OF CANCER, 2007, 97 (02) :177-182
[4]   Repression of 15-Hydroxyprostaglandin Dehydrogenase Involves Histone Deacetylase 2 and Snail in Colorectal Cancer [J].
Backlund, Michael G. ;
Mann, Jason R. ;
Holla, Vijaykumar R. ;
Shi, Qiong ;
Daikoku, Takikoku ;
Dey, Sudhansu K. ;
DuBois, Raymond N. .
CANCER RESEARCH, 2008, 68 (22) :9331-9337
[5]   Glucocorticoid resistance in inflammatory diseases [J].
Barnes, Peter J. ;
Adcock, Ion M. .
LANCET, 2009, 373 (9678) :1905-1917
[6]   Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling [J].
Bicaku, Elona ;
Marchion, Douglas C. ;
Schmitt, Morgen L. ;
Munster, Pamela N. .
CANCER RESEARCH, 2008, 68 (05) :1513-1519
[7]   Isoform-selective histone deacetylase inhibitors [J].
Bieliauskas, Anton V. ;
Pflum, Mary Kay H. .
CHEMICAL SOCIETY REVIEWS, 2008, 37 (07) :1402-1413
[8]   Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors [J].
Bradbury, C ;
Khanim, F ;
Hayden, R ;
Bunce, CM ;
White, DA ;
Drayson, MT ;
Craddock, C ;
Turner, BM .
LEUKEMIA, 2005, 19 (10) :1751-1759
[9]   Histone deacetylases: salesmen and customers in the post-translational modification market [J].
Brandl, Andre ;
Heinzel, Thorsten ;
Kraemer, Oliver H. .
BIOLOGY OF THE CELL, 2009, 101 (04) :193-205
[10]   HDACi - Targets beyond chromatin [J].
Buchwald, Marc ;
Kraemer, Oliver H. ;
Heinzel, Thorsten .
CANCER LETTERS, 2009, 280 (02) :160-167